GeneDx to Participate in Upcoming Investor Conferences
Get Alerts WGS Hot Sheet
Join SI Premium – FREE
GAITHERSBURG, Md.--(BUSINESS WIRE)-- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that company management will participate in upcoming investor conferences:
- Stifel 2025 Healthcare Conference
New York, New York
Fireside Chat: Wednesday, November 12 at 2:00 p.m. ET
- Jefferies Global Healthcare Conference
London, UK
Presentation: Wednesday, November 19 at 11:00 a.m. GMT
- Piper Sandler 37th Annual Healthcare Conference
New York, New York
Fireside Chat: Wednesday, December 3 at 1:30 p.m. ET
Live and archived webcasts of the presentations will be available on the “Events” section of the GeneDx investor relations website at ir.genedx.com/news-events/events.
About GeneDx
GeneDx (Nasdaq: WGS) is the global leader in rare disease diagnosis, transforming the way medicine is practiced by making genomics the starting point for health, not the last resort. We bring together unmatched clinical expertise, advanced technology, and the power of GeneDx Infinity™ – the largest rare disease dataset – built over 25 years from millions of genomic tests and deep clinical insights. This unparalleled foundation powers our ExomeDx™ and GenomeDx™ tests, giving clinicians the highest likelihood of delivering a timely, accurate diagnosis. GeneDx is shaping the future of healthcare by moving the standard of care from sick care to proactive healthcare. While our roots are in rare disease diagnosis, our commitment extends beyond – growing with the families we serve – as a trusted partner at every stage of life. For more information, visit genedx.com and connect with us on LinkedIn, Facebook, and Instagram.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251104392894/en/
Investor Relations Contact:
[email protected]
Media Contact:
[email protected]
Source: GeneDx
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FairJourney Bio Delivers Antibody Engineering for Novel Tumor-Conditional IL-12 Therapeutic Approach That Unlocks the Potential of Localized Cytokine Activation
- ICG: Oxy Capital Comments on the Half-Year Results of Irish Continental Group PLC (“ICG”) and the Independent Board’s Response to Its Letter
- Scottish Water Becomes First Utility in the World to Use Innovative New Technology to Reduce Laboratory Plastic Waste
Create E-mail Alert Related Categories
Business Wire, Press ReleasesRelated Entities
Stifel, Jefferies & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share